Berenberg Bank set a GBX 5,800 ($78.20) price target on AstraZeneca plc (LON:AZN) in a research report sent to investors on Tuesday.
Several other brokerages have also issued reports on AZN. Barclays PLC reaffirmed an "overweight" rating on shares of Astrazeneca PLC in a report on Monday, July 3rd. BidaskClub cut Astrazeneca PLC from a "buy" rating to a "hold" rating in a research report on Tuesday, July 11th. Investec raised shares of Astrazeneca PLC from a "hold" rating to a "buy" rating in a report on Wednesday, August 9th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and thirteen have assigned a buy rating to the company's stock. Astrazeneca PLC has an average rating of Hold and an average price target of $32.70.
The stock of AstraZeneca plc (ADR) (NYSE:AZN) is a huge mover today!
In related news, insider Nazneen Rahman acquired 39 shares of the company's stock in a transaction on Thursday, July 27th. The company has a market capitalization of $85.96 billion, a P/E ratio of 22.27 and a beta of 0.74. The value of the investment in Astrazeneca PLC increased from $2,537,000 to $124,285,000 a change of 4,798.9% since the last quarter. The firm's 50 day moving average is GBX 4,574.46 and its 200 day moving average is GBX 4,884.61. Astrazeneca PLC also saw some unusual options trading activity on Wednesday. This is an increase of 1,510% compared to the typical daily volume of 513 put options.
Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.41 by $0.46. During the same quarter in the previous year, the company posted $0.83 earnings per share. During the same period past year, the company posted $0.83 earnings per share. Analysts forecast that Astrazeneca PLC will post $1.90 EPS for the current year. If you are viewing this news story on another publication, it was illegally copied and republished in violation of US & worldwide copyright and trademark law. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and global copyright and trademark laws. The original version of this piece can be viewed at https://weekherald.com/2017/09/23/astrazeneca-plc-azn-given-buy-rating-at-sanford-c-bernstein.html.
The firm also recently declared a None dividend, which was paid on Monday, September 11th. Stockholders of record on Friday, August 11th were paid a dividend of $0.44 per share. The stock of AstraZeneca plc (ADR) (NYSE:AZN) earned "Buy" rating by Piper Jaffray on Wednesday, August 9. This dividend represents a yield of $2.75. Garrison Financial Corp now owns 18,058 shares of the company's stock worth $616,000 after acquiring an additional 86 shares in the last quarter. Fisher Asset Management LLC lifted its position in Astrazeneca PLC by 476.9% during the second quarter. Primecap Management Co. CA grew its holdings in Astrazeneca PLC by 32.1% in the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 13,315 shares of the company's stock worth $454,000 after acquiring an additional 94 shares in the last quarter. Finally, BlackRock Inc. increased its stake in shares of Astrazeneca PLC by 287,844.0% during the first quarter. BlackRock Inc. now owns 6,910,657 shares of the company's stock valued at $215,198,000 after buying an additional 6,908,257 shares in the last quarter. The stock was purchased at an average cost of GBX 4,370 ($58.92) per share, for a total transaction of £1,704.30 ($2,297.83).
AstraZeneca PLC (AstraZeneca), launched on June 17, 1992, is a biopharmaceutical company. The Firm focuses on discovery and development of products, which are then manufactured, marketed and sold.